Taken together, these observations suggest that pharmacological interventions that elicit robust activation of cortical 5-HT1A receptors and ERK phosphorylation could constitute an effective and novel strategy for RAADs which, like ketamine, could show efficacy in profoundly depressed and TRD patients. This evidence concerns the gene HTR1A and treatment resistant depression.